TheraPsil MDMA-Assisted Psychotherapy Training Program
TheraPsil announced an MDMA-Assisted Psychotherapy Training Program for healthcare professionals. The pilot phase was expected to begin in early 2024 and to build on completion of TheraPsil’s Fundamentals of Psilocybin-Assisted Psychotherapy training.
Provider
Details
Enrollment
Course Overview
TheraPsil announced a new MDMA-Assisted Psychotherapy Training Program as part of its work to expand access to psychedelic-assisted psychotherapy in Canada. The program was described as a response to growing demand for training and treatment in MDMA-assisted psychotherapy for trauma survivors. Curriculum development and rollout were to be led by Dr. Ingrid Pacey, a TheraPsil trainer who served as Principal Investigator of the MAPS Phase 2 MDMA trial in Vancouver. The organization said the pilot phase would launch in early 2024. The training was intended for practitioners who had successfully completed the didactic component of TheraPsil’s Fundamentals of Psilocybin-Assisted Psychotherapy training program. TheraPsil also noted that the expansion would support access to legal MDMA-assisted psychotherapy through Health Canada’s Special Access Program.
Who is this for?
Healthcare professionals and practitioners who have completed the didactic component of TheraPsil’s Fundamentals of Psilocybin-Assisted Psychotherapy training program.
Prerequisites
Successful completion of the didactic component of TheraPsil’s Fundamentals of Psilocybin-Assisted Psychotherapy training program.
About the Provider
TheraPsil is a Canadian nonprofit focused on legal access to psychedelic-assisted therapy for people in medical need. Its current public work spans patient navigation, prescriber and therapist training, referrals, and sustained advocacy around federal access pathways. The organization remains one of the clearest Canadian patient-access stakeholders because it links policy work to concrete care pathways. Current materials show active work on Project Solace, ongoing clinician upskilling, and new Manitoba progress around MDMA-assisted therapy.
View TheraPsil profileCourse Details
- PricePrice on request
- Lifecycle statusNo New Dates
- SkillsPsychotherapyPsilocybin TherapyMDMA-Assisted TherapyMDMA-assisted psychotherapyPsychedelic-assisted psychotherapyTrauma-informed careClinical trainingPatient-centred practiceSpecial Access Program (SAP) contextprofessional trainingTrauma-focused caretrauma-informed treatmentpatient access pathways
- Categories
Related Courses
View all coursesAre Ketamine Clinics Paving the Way for Legal Psychedelic Therapy?
By Double Blind
An article examining whether ketamine clinics could serve as a model for future legal psychedelic therapy. It discusses current ketamine clinic practices, emerging regulation questions, and how clinics are preparing for MDMA and psilocybin services.
Certificate in Psychedelic-Assisted Therapies & Research | CIISCIIS LogoCIIS Logo
By California Institute of Integral Studies (CIIS)
A 12-month certificate in psychedelic-assisted therapies and research housed in the CIIS Center for Psychedelic Therapies and Research. The program offers hybrid or online training covering clinical competencies, research, ethics, and culturally informed approaches.
Next cohort: Jul 13, 2026
Certificate in Psychedelic-Assisted Therapies and Research
By Fluence
A professional certificate program in psychedelic-assisted therapies and research offered by CIIS. It covers clinical and research foundations including pharmacology, research design, therapist competencies, and cultural and historical context.